A Pharmacodynamic Study of Pre-prostatectomy BKM120 in Men With High-risk, Localized Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 16 May 2018
At a glance
- Drugs Buparlisib (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 17 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.